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The larynx is the most common site of cancer in the head and neck region, whereas laryngeal cancers are listed as rare diseases by the "Office of Rare Diseases of the National Institutes of Health." Laryngeal cancers account for nearly 2-5% of new malignancies worldwide each year. Approximately 85-90% of these cancers are of the squamous cell type. Of the non-squamous cell types, neuroendocrine neoplasms are the most common, although they are an uncommon (less than 1% of all laryngeal tumors) variant and morphologically heterogeneous group of tumors of the larynx. [1, 2] Based on tissue origin, neuroendocrine tumors of the larynx are separated into two categories epithelial and neural. The epithelial tumors are divided into three subtypes based on degree of differentiation: typical carcinoid (well differentiated neuroendocrine carcinoma, grade 1), atypical carcinoid (moderately differentiated neuroendocrine carcinoma, grade 2 or large cell neuroendocrine carcinoma) and small cell neuroendocrine carcinoma (poorly differentiated neuroendocrine carcinoma, grade 3). Atypical carcinoid tumor is the most common of the neuroendocrine tumors of the larynx, followed by small cell neuroendocrine carcinoma, paraganglioma and the typical carcinoid.
[1] While paraganglioma is the most unique subtype of neural type tumor, [1, 3, 4] the typical carcinoid tumor
